An observational study in Melanoma, sponsored by Nantes University Hospital. Completed at 17 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-14.
Sponsored by Nantes University Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Melanoma by Nantes University Hospital — 3 open to participants now, 3 under way, none of them phase 3. Melanoma · Nantes University Hospital.
Among the 13 studies in Melanoma by Nantes University Hospital, this one is one of 2 that started in 2017, is one of 5 observational ones, and was the 8th registered.
3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.
Browse Melanoma studies →3 of the 13 studies in Melanoma by Nantes University Hospital are open now, in 1 country. Recruiting first, the newest first:
Nantes University Hospital · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 18+
Nantes University Hospital · Sites in France
Ages 18+
By country, each count listing its studies:
Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 350 is above the median of 187 across 489 observational studies indexed under Melanoma.
Median enrollment 44 across the 8 interventional studies, 700 across the 5 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Nantes University Hospital is the lead sponsor of 839 studies on the registry; 191 are open to participants now.
1 of the studies in Melanoma by Nantes University Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07354152Nantes University HospitalCOmparison of the Use of a PERforator Flap Versus Total Skin GRAft in the Management of Loss of Substance After Resection of Cutaneous Melanoma - Pilot Study | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Melanoma by Nantes University Hospital, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Nivolumab obtained European Marketing authorization in June 2015. Before this date, a Temporary Authorization for Use (ATU) Program in France for nivolumab was set up between September 2014 and August 2015. This program enrolled approximately 600 melanoma patients (unresectable or metastatic).
It appears relevant to conduct a study on patients treated during the ATU to assess thoroughly patient characteristics, efficacy, safety, and patterns of use of nivolumab in real-life conditions.
In order to reach goals of this study, collaboration had been established between BMS and the RIC-Mel network (network for Research and Clinical Investigational Research on Melanoma) (NCT03315468).
The RIC-Mel network has set up a national database in order to reference the active file of melanoma patients in France. The RIC-Mel database, supported by Nantes University Hospital, had been approved by French authorities (CCTIRS and CNIL). The RIC-Mel network is coordinated by Pr B. DRENO (Nantes University Hospital) and Pr C. LEBBE (Saint-Louis Hospital, AP-HP, Paris). Nowadays, 49 centres located all over the country are participating, with more than 19,000 melanoma patients included in the database. The RIC-Mel database is referred as one of the privileged access to any research program on melanoma by the Cancerology Group (GCC) of the French Society of Dermatology .
Based on this, BMS and the RIC-Mel network had established a partnership to set up a study in order to estimate the overall survival of melanoma patients treated by Nivolumab during the French ATU program.
Data are collected in the RIC-Mel database by participating centres. Information of centres, follow-up of activity, data reviewing and extractions are realized by the RIC-Mel network. Data analysis is performed by BMS following a developed statistical protocol.
Patients included in the study were patients with unresectable or advanced metastatic melanoma, which received at least one of Nivolumab, dispensed during the French ATU program.
patients
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
This study is an observational one - there is no change to the routine care. Patients received the Nivolumab independently of the study. Only data will be collected during this project.
This study also gives Nivolumab. No intervention listed here names it: that was found by reading the record.
Overall Survival of patients included in the study thanks to subgroups of interest
Overall survival is defined as the time from index date (initiation of Nivolumab) until date of death due to any cause. Overall survival will be censored on the last date a subject was known to be alive. Estimates of survival rates will be realized for 1-year and 2-year survival. Median time will also be calculated. Subgroups of interest are described in the description of the first Secondary Outcome Measure. Safety Issue: No
Time frame: 2 years
Distribution of melanoma patients included in the study in all subgroups of interest thanks to their clinical features at the time of treatment initiation
Subgroups of interest, based on information collected in medical records, were : * ECOG performance status (PF). ECOG PF is attempted to quantify cancer patients' general well-being and activities of daily life. The classifications were 0, 1 or ≥2. * LDH level. This level is considered as a prognostic factor: higher the LDH level, the worst the prognosis. The classifications were ≤Upper Limit of Normal (ULN), \>ULN, \>2 ULN or N/R (Unknown). * History of brain metastasis. These metastases are considered as one of the most difficult-to-treat complications of melanoma. The classifications were No or Yes. * Line of therapy. The classifications were 0, 1, 2 or \>2. * BRAF status. BRAF is a proto-oncogene. Melanoma patients with BRAF mutation are eligible to targeted therapy.The classifications were Yes (mutated), No (wild-type) and Unknown (no research). * Number of metastatic sites. Safety Issue: No
Time frame: Day 1
Proportion of melanoma patients included in the study categorized by genders overall and by subgroups of interest
Distribution of females and males. This analyse will be performed for all the study population and by subgroups of interest (as defined in the primary Outcome Measure).Safety Issue: No
Time frame: Day 1
Distribution of age of melanoma patients included in the study overall and by subgroups of interest
Age of patients is the age at the start of Nivolumab treatment Safety Issue: No
Time frame: Day 1
Description of Nivolumab treatment of melanoma patients included in the study
Average and median of Nivolumab treatment duration and infusion number will be assessed. Median time to discontinuation, whatever the reason and median time to discontinuation of dose related to adverse events. Distribution of reasons for discontinuation. Safety Issue: No
Time frame: 2 years
Incidence of select grade 3, 4 and 5 adverse events (AE) in melanoma patients included in the study and related to Nivolumab treatment
An AE is defined as any undesirable experience or manifestation associated with the use of a medical product in a patient. AEs are categorized by grades, which refer to severity : Grade 3 - Severe or medically significant but not immediately life-threatening, hospitalization or prolongation of hospitalization indicated, disabling, limiting self-care activities of daily living, Grade 4 - Life-threatening consequences, urgent intervention indicated, Grade 5 - Death related to AE. Proportion of patients with at least one or more select AE, distribution, average and median time of AE occurrence, duration and evolution of AEs as well as description of action on Nivolumab treatment will also be assessed. Safety Issue: Yes
Time frame: 2 years
Progression-free survival of melanoma patients included in the study
Progression-free survival is defined as the time since Nivolumab initiation to either the first disease progression date or at last known tumour assessment date, or death due to any cause, whichever occurs first. Safety Issue: No
Time frame: 2 years
Objective response rate of melanoma patients included in the study
Objective response rate as the number of subjects with a best objective response of either a partial response of a complete response. Objective response rate is the proportion of patients with an objective response. Safety Issue: No
Time frame: 2 years
Ran from Mar 2017 to primary completion in Sep 2018, 17 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.